<DOC>
	<DOCNO>NCT01468623</DOCNO>
	<brief_summary>The purpose study compare OnDose® base pharmacokinetic administration 5-FU versus standard Body Surface Area ( BSA ) base administration 5-FU patient metastatic colorectal cancer treat mFOLFOX6 , without bevacizumab , determine use OnDose® achieve improvement Overall Response Rate ( ORR ) relative BSA dose response .</brief_summary>
	<brief_title>Study Comparing Optimized 5-FU Dosing Standard Dosing Metastatic Colorectal Cancer Patients Treated With mFOLFOX6</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Selection Criteria : Patients histologically confirm metastatic colorectal cancer No prior chemotherapy treatment metastatic colorectal cancer At least one measurable lesion CT MRI ≥ 20 mm ( conventional CT scan ) ≥ 10 mm ( spiral CT scan ) ECOG Performance Status ( ECOGPS ) status ≤ 2 At least 18 year age Life expectancy &gt; 6 month Must able willing give write informed consent Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use acceptable contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) , must negative serum urine pregnancy test within 1 week prior begin treatment trial . Nursing patient exclude . Sexually active men must also use acceptable contraceptive method ( abstinence , condom ) . ANC count great equal 1,500/ mm³ Platelets great equal 100,000/ mm³ Serum creatinine less equal 2x upper limit normal ( normal range ( male ) : 97137 mL/min ; ( female ) : 88128 mL/min ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 3x upper limit normal ( ≤ 5.0 x ULN acceptable liver tumor involvement ) ( ALT normal range : &lt; 41 iu/L ( male ) , &lt; 31 iu/L ( female ) ; AST normal range : &lt; 37 iu/L ( male ) , &lt; 31 iu/L ( female ) ) . Prothrombin Time ( PT ) , activate partial thromboplastin time ( aPTT ) INR ≤ 1.5 x ULN ( INR normal range : 0.81.2 ) therapeutic range anticoagulation . Hemoglobin great equal 9 gm/dl ( may correct transfusion prior 5FU treatment investigator approval ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Colorectal cancer , metastatic</keyword>
	<keyword>FOLFOX6</keyword>
	<keyword>5-FU</keyword>
	<keyword>First line</keyword>
	<keyword>bevacizumab</keyword>
</DOC>